Scribe Therapeutics is preparing to take its first cardiometabolic programme into the clinic in mid-2026, positioning STX-1150 as a potentially...
On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based...
Some of the best links we picked up around the internet
Researchers in Japan have developed a CRISPR-Cas-based system to edit epigenetic marks in mouse sperm, enabling direct investigation of whether DNA...
nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...
American researchers have developed an RNA-based platform that uses CRISPR epigenetic editors to durably silence or activate genes in primary human T...
